Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3289-3303

  Zhu, Yaqin ^a   Cheng, Liang ^a   Cheng, Lifang ^a   Huang, Fazhen ^a   Hu, Qing ^a   Li, Ling ^a   Tian, Chenmin ^a   Wei, Lin ^a   Chen, Dawei ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

cellular uptake; folate; liposomes; TAT peptide; tumor targeted delivery

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; FOLIC ACID; LIPOSOME; MACROGOL DERIVATIVE; PEPTIDE; TRANSACTIVATOR PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG SCREENING; FEMALE; HUMAN; KB CELL LINE; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; GENE PRODUCTS, TAT; HUMANS; KB CELLS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; PEPTIDES; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84936109742     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1418-z     Document Type: Article

References (40)

1. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-84.
2. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17-18):812-8.
3. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-46.
4. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharm Res. 2010;62(2):90-9.
5. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34.
6. Li Y, Wang J, Wientjes MG, Au JLS. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev. 2012;64(1):29-39.
7. Jang S, Wientjes MG, Lu D, Au JLS. Drug delivery and transport to solid tumors. Pharm Res. 2003;20(9):1337-50.
8. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559-93.
9. Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012;162(1):45-55.
10. James DB, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-26.
11. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. 2005;48(11):3729-35.
12. Kunath K, Merdan T, Hegener O, Häberlein H, Kissel T. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med. 2003;5(7):588-99.
13. Levchenko TS, Rammohan R, Volodina N, Torchilin VP, Nejat D. Tat Peptide-mediated intracellular delivery of liposomes. In: Abelson JN, Simon MI, editors. Methods in enzymol. New York: Academic; 2003. p. 339-49.
14. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008;60(4-5):548-58.
15. Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta (BBA) Biomembr. 2004;1665(1-2):48-56.
16. Vivès E. Cellular uptake of the Tat peptide: an endocytosis mechanism following ionic interactions. J Mol Recognit. 2003;16(5):265-71.
17. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem. 2003;278(33):31192-201.
18. Brooks H, Lebleu B, Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev. 2005;57(4):559-77.
19. Kuai R, Yuan W, Qin Y, Chen H, Tang J, Yuan M, et al. Efficient delivery of payload into tumor cells in a controlled manner by Tat and thiolytic cleavable PEG co-modified liposomes. Mol Pharm. 2010;7(5):1816-26.
20. Koren E, Apte A, Jani A, Torchilin VP. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release. 2012;160(2):264-73.
21. Takara K, Hatakeyama H, Ohga N, Hida K, Harashima H. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int J Pharm. 2010;396(1-2):143-8.
22. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release. 2003;92(1-2):49-67.
23. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta (BBA) Biomembr. 1995;1233(2):134-44.
24. Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, et al. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci. 2010;99(8):3542-51.
25. Pan X, Wang H, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft Model. Pharm Res. 2003;20(3):417-22.
26. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A. 2001;98(15):8786-91.
27. Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93(8):1980-92.
28. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-8.
29. Wu J, Liu Q, Lee RJ. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm. 2006;316(1-2):148-53.
30. Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2010;27(1):161-74.
31. Peng SF, Tseng MT, Ho YC, Wei MC, Liao ZX, Sung HW. Mechanisms of cellular uptake and intracellular trafficking with chitosan/DNA/poly(γ-glutamic acid) complexes as a gene delivery vector. Biomaterials. 2011;32(1):239-48.
32. Qhattal HSS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm. 2011;8(4):1233-46.
33. Lee JS, Ankone M, Pieters E, Schiffelers RM, Hennink WE, Feijen J. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes. J Control Release. 2011;155(2):282-8.
34. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435-46.
35. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
36. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182-95.
37. Un K, Sakai-Kato K, Oshima Y, Kawanishi T, Okuda H. Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. Biomaterials. 2012;33(32):8131-41.
38. Kitchens KM, Kolhatkar RB, Swaan PW, Ghandehari H. Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm. 2008;5(2):364-9.
39. Vandenbroucke RE, De Smedt SC, Demeester J, Sanders NN. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochim Biophys Acta (BBA) Biomembr. 2007;1768(3):571-9.
40. Ruan G, Agrawal A, Marcus AI, Nie S. Imaging and tracking of Tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc. 2007;129(47):14759-66.